New cocktail of cancer drugs shows promise in early pancreatic cancer trial
NCT ID NCT01660971
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or couldn't be surgically removed. The main goal was to find the safest dose and see how well patients tolerated the treatment. Researchers also tracked how long patients lived and how long the cancer stayed under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.